Pharm 8

Front 1

ganglion blockers and NMJ blockers make up

Back 1

antinicotinic drugs

Front 2

M1 subtype

Back 2

CNS, sympathetic postganglionic cell bodies and many presynaptic sites

Front 3

M2 subtype

Back 3

myocardium, smooth muscle organs, and some neuronal sites

Front 4

M3 subtype

Back 4

effector cell membranes, especially glandular and smooth muscle cells

Front 5

M4 subtype and M5

Back 5

greater role in CNS than periphery

Front 6

Atropine

Back 6

prototype of antimuscarinics

Front 7

tertiary antimuscarinic common use

Back 7

eye or CNS effects

Front 8

quanternary amine antimuscarinic common use

Back 8

peripheral effects with reduced CNS effects

Front 9

atropine excretion

Back 9

50% urine unchanged; remaining hydrolysis and conjugation products

Front 10

how long do atropine effects last

Back 10

>72 hours in eye; rapidly declines elsewhere

Front 11

atropine MOA

Back 11

reversible blockade of cholinomimetic actions at muscarinic receptors (M1, M2, and M3)

Front 12

muscarinic drugs that are inverse agonists

Back 12

atropine, pirenzepine, trihexyphenidyl, AF-DX 116, 4-DAMP, and a methyl derivative of scopolamine

Front 13

tissues most sensitive to antimuscarinics (atropine)

Back 13

salivary, bronchial, and sweat glands

Front 14

antimuscarinics and the eye

Back 14

mydriasis (dilation) and cycloplegia (weaken contraction of ciliary muscle)

Front 15

cardiovascular and antimuscarinics

Back 15

tachycardia=blockade of vagal slowing

Front 16

atropine in presence of high vagal tone

Back 16

significantly reduce PR interval by blocking muscarinic receptors in AV node

Front 17

parasympathetic innervation of vessels

Back 17

stimulation dilates coronaries; constricts skeletal muscle vascular bed

Front 18

atropine on lungs

Back 18

bronchodilation and decreased secretions

Front 19

atropine and GI tract

Back 19

reduces motility and secretion for basal secretion

Front 20

atropine and GU

Back 20

relaxes smooth muscle of ureters and bladder wall slowing voiding

Front 21

antimuscarinic used in motion sickness

Back 21

scopolamine

Front 22

mydriasis for funduscopic exam

Back 22

alpha-adrenoceptor stimulant drugs; antimuscarinics work, but are only used if prolonged action required or cycloplegia

Front 23

inhalation antimuscarinic used in asthma

Back 23

ipratropium; recently tiotropium in COPD

Front 24

antimuscarnic somewhat selective for M3 and used to relieve bladder spasm

Back 24

oxybutynin

Front 25

pralidoxime

Back 25

cholinesterase regenerator cmpd-doesn't reverse CNS effects

Front 26

pyridostigmine use

Back 26

pretreatment-reversible enzyme inhibitor of irreversible organophosphate inhibitor

Front 27

rapid-onset mushroom poisoning symptoms

Back 27

muscarinic excess=nausea, vomiting, diarrhea, urinary urgency, vasodilation, reflex tachycardia, sweating, salivation, sometimes bronchoconstriction

Front 28

atropine OD treatment

Back 28

mostly symptomatic treatment

Front 29

cardiovascular and ganglionic blockers

Back 29

marked decrease in arteriolar and venomotor tone (sympathetic vasoconstrictor fibers); BP falls, marked in upright position (postural reflexes blocked)

Front 30

trimethaphan

Back 30

ganglion blocking drug; hypertensive emergencies and dissecting aortic aneurysm to produce hypotension